KRAS and non-small cell lung carcinoma: Thus, this study was conducted to construct a risk model from a tissue IRPS (TMB, PD-L1, TP53, KRAS, EGFR and SMAD4) in Qujing patients with advanced NSCLC to establish a comprehensive prognostic biomarker that can predict ICI responsiveness in Qujing populations with advanced NSCLC.